Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin plus radiotherapy as adjuvant treatment for HER2-overexpressing high-risk UTUC after radical surgery
ChiCTR2400080838Phase 2Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Feb 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of disitamab vedotin in upper tract urothelial carcinoma (UTUC) (2 arms), sponsored by Peking University First Hospital. Primary endpoint: Disease-free survival. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
disitamab vedotin
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on ChiCTR2400080838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080838.